Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind BMS-986178 (anti-CD134) (Ab209739) with the EC50 of 38.0 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Ivuxolimab (anti-CD134) (Ab182815) with the EC50 of 32.7 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Tavolixizumab (anti-CD134) (Ab182830) with the EC50 of 41.2 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Cudarolimab (anti-CD134) (Ab182885) with the EC50 of 112.0 ng/mL.
OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.
生物活性
Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind BMS-986178 (anti-CD134) (Ab209739) with the EC50 of 38.0 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Ivuxolimab (anti-CD134) (Ab182815) with the EC50 of 32.7 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Tavolixizumab (anti-CD134) (Ab182830) with the EC50 of 41.2 ng/mL. Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Cudarolimab (anti-CD134) (Ab182885) with the EC50 of 112.0 ng/mL.
31.6- 49.3 kDa, under reducing conditions; 28.9-49.9 kDa, under non-reducing conditions
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, pH 7.4
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.5 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
Store at -20°C for 1 year. Avoid freeze/thaw cycle.
图片
Recombinant Human OX40/TNFRSF4 Protein (rp181285) - ELISA Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind BMS-986178 (anti-CD134) (Ab209739) with the EC₅₀ of 38.0 ng/mL.
Recombinant Human OX40/TNFRSF4 Protein (rp181285) - ELISA Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Ivuxolimab (anti-CD134) (Ab182815) with the EC₅₀ of 32.7 ng/mL.
Recombinant Human OX40/TNFRSF4 Protein (rp181285) - ELISA Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Tavolixizumab (anti-CD134) (Ab182830) with the EC₅₀ of 41.2 ng/mL.
Recombinant Human OX40/TNFRSF4 Protein (rp181285) - ELISA Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Cudarolimab (anti-CD134) (Ab182885) with the EC₅₀ of 112.0 ng/mL.
Recombinant Human OX40/TNFRSF4 Protein (rp181285) - SDS-PAGE 3 μg/lane of Recombinant Human OX40/TNFRSF4 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 31.6- 49.3 kDa under reducing conditions and 28.9-49.9 kDa under non-reducing conditions.